NCT07236229 The Effects of Immersive Virtual Reality in Patients With Grade 1-2 Adhesive Capsulitis
| NCT ID | NCT07236229 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bahçeşehir University |
| Condition | Adhesive Capsulitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2025-11-28 |
| Primary Completion | 2026-01-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2025-11-28 with a primary completion date of 2026-01-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Adhesive capsulitis (frozen shoulder) is a complex condition characterized by inflammation, fibrosis, and restriction of movement in the shoulder capsule, significantly limiting an individual's participation in daily living activities. It is most commonly observed in individuals aged between 40 and 60 years, and its treatment frequently involves approaches such as manual therapy, exercise, corticosteroid injections, and electrotherapy. However, these conventional methods may be limited by factors such as lack of motivation, pain-related avoidance behavior, and poor treatment adherence. Today, immersive virtual reality technologies introduce a new dimension to rehabilitation by gamifying exercise, providing sensory feedback, and enabling graded exposure through mechanisms such as distraction and engagement. They also enhance motivation and compliance with exercise programs. Studies in the literature have reported that virtual reality-based exercise is an effective method for reducing pain levels in patients diagnosed with frozen shoulder. However, only a limited number of studies have specifically examined the effects of immersive virtual reality in patients with adhesive capsulitis. To date, no study has investigated the impact of immersive virtual reality interventions on sleep and cognitive functions in these patients. Furthermore, the combined effect of patient education, home exercise programs, and immersive virtual reality therapy has not yet been explored. For these reasons, the present study aims to investigate the effects of immersive virtual reality-based exercise therapy on pain, functionality, sleep, and cognitive functions in patients with Grade 1-2 adhesive capsulitis.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with adhesive capsulitis by a doctor * Classified as Grade 1-2 adhesive capsulitis * Receiving physiotherapy for adhesive capsulitis for the first time * Aged between 18 and 64 years * Suitable for using a VR headset Exclusion Criteria: * Previous history of physiotherapy * Presence of any mental disorder * Recent surgery or any shoulder condition (e.g., fractures around the shoulder region) that contraindicates shoulder mobilization * History of receiving injections
Contact & Investigator
Hande B Gocen, PhD (c)
PRINCIPAL INVESTIGATOR
Istanbul Gelisim University
Frequently Asked Questions
Who can join the NCT07236229 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Adhesive Capsulitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07236229 currently recruiting?
Yes, NCT07236229 is actively recruiting participants. Contact the research team at handegocen@outlook.com for enrollment information.
Where is the NCT07236229 trial being conducted?
This trial is being conducted at Küçükçekmece, Turkey (Türkiye).
Who is sponsoring the NCT07236229 clinical trial?
NCT07236229 is sponsored by Bahçeşehir University. The principal investigator is Hande B Gocen, PhD (c) at Istanbul Gelisim University. The trial plans to enroll 36 participants.